Security
Galapagos NV Ordinary Shares · GLPGF
GLPGFOTCCommon stockCurrentCIK 1421876Updated Oct 14, 2026
Name history
GALAPAGOS NV · through May 6, 2026
GLPGF price & chart
Loading TradingView…
OTC:GLPGF on TradingView ↗About the company
Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical-stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first-in-class and best-in-class BCMAxCD3 T-cell engager for autoimmune diseases. Backed by deep deal-making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high-quality assets with clear potential to deliver meaningful patient impact and long-term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · EURSource
Source
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossEUR | 320,884,000Source | 74,082,000Source | 211,697,000Source | -217,991,000Source |
| Additional Financial Items | ||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableEUR | 86,588,000Source | -31,055,000Source | -39,114,000Source | 68,984,000Source |
| AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossEUR | 55,875,000Source | 45,499,000Source | — | — |
| AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociatesEUR | 1,085,000Source | 52,488,000Source | — | — |
| AdjustmentsForIncomeTaxExpenseEUR | -18,138,000Source | -1,705,000Source | 11,689,000Source | 2,844,000Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableEUR | 33,813,000Source | -53,429,000Source | 31,817,000Source | -2,083,000Source |
| AdjustmentsForSharebasedPaymentsEUR | 23,999,000Source | 19,886,000Source | 56,718,000Source | 88,506,000Source |
| GeneralAndAdministrativeExpenseEUR | 147,333,000Source | 117,245,000Source | 128,289,000Source | 144,931,000Source |
| GoodwillEUR | — | 70,010,000Source | 69,557,000Source | 69,813,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesEUR | 372,000Source | -406,000Source | 8,170,000Source | 4,433,000Source |
| InterestPaidClassifiedAsOperatingActivitiesEUR | 464,000Source | 689,000Source | 3,809,000Source | 12,463,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesEUR | 51,281,000Source | 97,518,000Source | 69,907,000Source | 4,839,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | 3,273,000Source | 4,924,000Source | 6,771,000Source | 8,182,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesEUR | 462,000Source | 3,000Source | 2,426,000Source | 739,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesEUR | 155,000Source | 65,390,000Source | 567,000Source | 9,558,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Total RevenueEUR | 1,112,248,000Source | 275,649,000Source | 239,724,000Source | 505,280,000Source |
| Additional Financial Items | ||||
| AuditorsRemunerationForTaxServicesEUR | 15,100Source | 49,500Source | — | — |
| BasicEarningsLossPerShareEUR/shares | 4.87Source | 1.12Source | 3.21Source | -3.32Source |
| CurrentTaxExpenseIncomeEUR | 792,000Source | 1,301,000Source | 5,928,000Source | 4,071,000Source |
| DeferredTaxExpenseIncomeEUR | -19,413,000Source | -3,104,000Source | 3,685,000Source | -1,227,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossEUR | — | — | 72,000Source | -1,227,000Source |
| DilutedEarningsLossPerShareEUR/shares | 4.87Source | 1.12Source | 3.21Source | -3.32Source |
| EmployeeBenefitsExpenseEUR | 228,188,000Source | 146,943,000Source | 164,883,000Source | 346,997,000Source |
| GeneralAndAdministrativeExpenseEUR | 147,333,000Source | 117,245,000Source | 128,289,000Source | 144,931,000Source |
| ImpairmentLossRecognisedInProfitOrLossGoodwillEUR | 69,404,000Source | 0Source | — | — |
| IncomeTaxExpenseContinuingOperationsEUR | -18,621,000Source | -1,803,000Source | 9,613,000Source | 2,844,000Source |
| InterestExpenseEUR | 1,034,000Source | 911,000Source | 1,770,000Source | 6,967,000Source |
| OtherEmployeeExpenseEUR | 14,615,000Source | 9,136,000Source | 6,682,000Source | 18,067,000Source |
| OtherFinanceCostEUR | 2,863,000Source | 1,670,000Source | 2,613,000Source | 17,679,000Source |
| OtherIncomeEUR | 53,493,000Source | 40,773,000Source | 47,272,000Source | 46,848,000Source |
| OtherOperatingIncomeExpenseEUR | 53,493,000Source | 40,773,000Source | 47,272,000Source | 46,848,000Source |
| ProfessionalFeesExpenseEUR | — | — | 68,000Source | — |
| ProfitLossAttributableToOwnersOfParentEUR | 320,884,000Source | 74,082,000Source | 211,697,000Source | -217,991,000Source |
| ProfitLossBeforeTaxEUR | 300,871,000Source | -3,085,000Source | 5,625,000Source | -215,147,000Source |
| ProfitLossFromOperatingActivitiesEUR | 295,039,000Source | -188,338,000Source | -88,263,000Source | -267,520,000Source |
| ResearchAndDevelopmentExpenseEUR | 459,421,000Source | 335,459,000Source | 241,294,000Source | 515,083,000Source |
| RevenueFromInterestEUR | 46,339,000Source | 89,378,000Source | — | — |
Filing attachments
tm2622771d1_ex99-1.htm · 6-K · 2026-08-12
Exhibit 99.1 Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig approval Maintain year-end 2026 cash and financial investments balance guidance of ~€2B, and now includes €50M share repurchase Mechelen, Belgium; August 10, 2026, 22.01 CET; reg…
Read attachment ↗tm2622771d1_ex99-2.htm · 6-K · 2026-08-12
Exhibit 99.2 Half-Year Financial Report 2026 OTHER INFORMATION 1 Galapagos NV Half-Year Financial Report 2026 ACTIVE/208711980.4 About This Report This report contains information required under Belgian law. Lakefront Biotherapeutics NV is a limited liability company organized under the laws of Belgium, having its registered office at Schaliënhoevedreef 20T, 2800 Mechelen, Belgium and registered with the Crossroads Enterprise Database (RPR Antwerp – division Mechelen) under n…
Read attachment ↗tm2612973d1_ex99-1.htm · 6-K · 2026-04-29
Exhibit 99.1 Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026 Mechelen, Belgium; April 28, 2026, 22:01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the Company’s Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) held on 28 April 2026 were approved. The AGM approved, amongst other items: The Annual Report and the Remuneration Report The …
Read attachment ↗d927249dex991.htm · 6-K · 2026-03-31
Exhibit 99.1 Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities Opportunity to develop a potential first-in-class & best-in-class…
Read attachment ↗d927249dex992.htm · 6-K · 2026-03-31
Exhibit 99.2 Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases Conference Call March 31, 2026 Forward-Looking Statements This presentation contains forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,”…
Read attachment ↗d54917dex991.htm · 6-K · 2026-03-30
Exhibit 99.1 Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders’ Meetings Mechelen, Belgium; March 26, 2026, 21:01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) today published its annual report for the financial year 2025 and announced that its Annual Shareholders’ Meeting (AGM) and an Extraordinary Shareholders’ Meeting (EGM) will be held sequentially on Tuesday, April 28, 2026 at 14:00 CET and 15:00 CET at Schaliënhoevedreef 20T,…
Read attachment ↗